logo-loader

Emyria gains access to world-class data platform under Palantir Foundry Builders Program

Last updated: 12:11 07 Oct 2021 AEDT, First published: 12:03 07 Oct 2021 AEDT

Emyria Ltd - Emyria gains access to world-class data platform Under Palantir Foundry Builders Program

Emyria Ltd (ASX:EMD) has secured access to one of the world’s most sophisticated data platforms after joining Palantir’s Foundry Builders Program.

The scheme, run by major software company Palantir Technologies, gives select companies access to powerful and highly secure data integration and analysis software that’s typically only available to major enterprises.

Now, as part of the program’s second cohort, Emyria will leverage the platform as the backbone of its real-world evidence (RWE (ETR:RWE)) — information gathered outside random clinical trials.

Access to the data podium will also accelerate Emyria’s data-guided drug development programs that are currently targeting Food and Drug Administration (FDA) and Therapeutic Goods Administration (TGA) registrations.

Platform to accelerate new treatments

Speaking to the initiation to join the program, Emyria managing director Dr Michael Winlo said: “We’re delighted to be selected to be part of the global Palantir ecosystem and leveraging one of the world’s most sophisticated and powered data platforms for our proprietary real-world evidence.

“RWE is being increasingly used by major global drug regulators, like the FDA, to evaluate the safety and efficacy of new treatments.

“Palantir Foundry greatly improves our ability to secure, integrate, generate and analyse our real-world evidence — both internally and with our global partners — meaning we can deliver on our mission to develop new treatments and improve patient care, faster.

Palantir chief operating officer Shyam Sankar said: “We’re excited to expand the use of Palantir Foundry to yet another group of hypergrowth startups.

“These organisations have ambitious goals and timelines— they see building on Foundry as the cheapest and fastest way to market.

“Foundry’s software-defined data integration and no-code applications mean customers can onboard new customers and develop new apps at a speed and cost that was previously inconceivable.”

The Palantir program

Palantir Technologies, a US-based software stock with a US$54 billion market cap, was co-founded by entrepreneur and PayPal (NASDAQ:PYPL) brain Peter Thiel.

The company establishes data platforms for a wide range of clients that need to scaffold complex and often sensitive data.

Some of the noteworthy organisations that use Palantir’s services include the FDA, the National Institutes of Health and pharmaceutical stalwart Sanofi.

Its Foundry Builders program is designed to give emerging companies access to a data podium they couldn’t regularly get their hands on.

Dr Winlo previously worked with Palantir’s health data team in San Francisco, meaning Emyria can access the platform under a markedly reduced subscription model.

Essentially, it provides subscribers with a central operating system — a backbone, if you will — for their data.

It’s designed to scale amid increasing complexity, meaning it can support companies as they grow while powering data-driven decision-making.

Tie-ins with Emyria

For Emyria, access to this world-class data platform provides it with a centralised system to integrate its real-world evidence.

It’s one of 10 companies that gain access to the podium as part of the second cohort of Palantir’s Foundry program.

Recently, the FDA released a guidance document that states it is important to make sure all data used to generate RWE has the highest standards of data accuracy, completeness, provenance and traceability.

RWE is also being increasingly used in the evaluation of new drug registrations by major global regulators like the FDA.

Under the program, Emyria will have access to the full Palantir Foundry stack, greatly enhancing its data infrastructure, security, integration and analysis capabilities.

It will support the ASX-lister’s growing RWE asset, which covers health outcome data for more than 5,000 patients with complex medical conditions and receiving unregistered treatments.

Overall, Emyria’s RWE provides unique dose-response insights and intellectual property that supports its active and developing drug development programs.

Winlo concluded: “By using Palantir Foundry, we can generate dose-response insights and clinical decision support tools using advanced statistical and machine learning algorithms.

“We are also able to capture all relevant intellectual property related to our research while securely protecting patient privacy.”

Australian Strategic Materials signs US$600 million LoI

Rowena Smith, CEO and managing director of Australian Strategic Materials Ltd (ASX:ASM, OTC:ASMMF), joins Jonathan Jackson in the Proactive studio to discuss the company’ s Dubbo Project, in Central West New South Wales. This project aims to extract and process critical minerals and rare earth...

3 hours, 17 minutes ago